Sorted By:


A New Negotiation: Moving Payment for Medicines from Volume to Value

PhRMA  |  Video

Across the health care system there is a movement to better pay for services based on outcomes. At this event on February 23, 2017, America's biopharmaceutical companies discussed ways the private prescription medicine marketplace can evolve to produce and reward better value for patients....

#RarePOV Conversation Generates Strong Enthusiasm for Rare Disease Day on February 28th

PhRMA  |  Blog Post

You can find information on events in other countries on the global Rare Disease Day website.

Ted Kyle, RPh, MBA

PhRMA  |  Biography

Ted holds two degrees from the University of North Carolina at Chapel Hill: a BS in Pharmacy and an MBA.

ICYMI – IMS Institute – Branded net medicine price increases “lowest in past five years”

PhRMA  |  Blog Post

Learn more at

Cost of mental illness underscores need for new treatments

PhRMA  |  Blog Post

Learn more in the 2016 “Medicines in Development for Mental Illnesses” report, and see the full list of medicines currently in development to treat mental illnesses.

New Report: Nearly 4.5 Million U.S. Jobs and $1.2 Trillion Economic Output Supported by Biopharmaceutical Sector in 2014

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.

Medicare Monday: New study further confirms increased use of generics after Part D

PhRMA  |  Blog Post

Learn more at

PhRMA Statement on FDA User Fees

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.

Pharmaceutical Organizations Announce Key Principles to Foster Supply Chain Security and Integrity

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested over $500 billion in the search for new treatments and cures, including an estimated $49.5 billion in 2011 alone.

New Medicines Made Available through PDUFA

PhRMA  |  Graphic

The Prescription Drug User Fee Act (PDUFA) has helped bring more than 1,500 new safe and effective medications to patients.

Welcome to the new

PhRMA  |  Blog Post

Explore PhRMA’s new digital home at

New Study: Substantial rebates negotiated in Medicare Part D

PhRMA  |  Blog Post

This report is further evidence of the robust negotiating power of Part D plans and how they secure rebates and discounts to keep costs low for beneficiaries and taxpayers.

New Report: Many Exchange Plans Burden the Most Vulnerable Patients with High Out-of-Pocket Costs for Vital Medicines; Patients left with limited access

PhRMA  |  Press Release

Eric Hargis, Colon Cancer Alliance CEO, stated, “Colorectal cancer is the second leading cause of cancer deaths in America; however, thanks to the development of personalized therapies and other innovative treatments the prognosis for colorectal cancer patients is the best it has ever been and today there are more than one million survivors in the United States.

New Questions About Why More Women Than Men Have Alzheimer's

From Hope To Cures  |  From Our Network

"That was alarming," said Shives, who is in the early stages of Alzheimer's, which struck at a younger-than-usual age and forced her retirement as a college counselor.

A Sea Change in Treating Heart Attacks

From Hope To Cures  |  From Our Network

At Yale-New Haven Hospital, where half the patients used to have to wait at least 150 minutes before their arteries were opened, the median time is now 57 minutes.

Key Industry and PhRMA Facts

PhRMA  |  Codes & Guidelines

 PhRMA is headquartered in Washington, D.C., and also has offices in Albany, Atlanta, Baton Rouge, Boston, Denver, Indianapolis, Olympia, St.

The Value Collaborative: Advancing private market solutions to achieve better health, lower costs

PhRMA  |  Blog Post

That is why we have proposed commonsense policy solutions to address the legal and regulatory barriers that currently exist and why we, as an industry, are investing in the development and use of tools for better measurement of outcomes and the creation of value frameworks that keep the needs of the patient in mind.

What they are saying about new hepatitis C cure: “That's actually a great deal”

PhRMA  |  Blog Post

That's actually a great deal.

Exploring the new era of medicine

PhRMA  |  Blog Post

To learn more about the positive impact of the work being done by America’s biopharmaceutical companies, visit

Key Facts Card

PhRMA  |  Fact Sheet

Relentless scientific inquiry in drug development is shifting the odds in the fight against some of the world’s most challenging diseases. Industry facts from research and development to value of medicines to economic impact are outlined in the Fact Sheet below....

World Anti-Counterfeiting Day Puts Spotlight On Growing Foreign Counterfeit Medicine Threat

PhRMA  |  Press Release

PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.

World AIDS Day: Making progress

PhRMA  |  Blog Post

On average, it costs $2.6 billion and takes between 10 to 15 years to bring a new medicine to patients.

World Cancer Day: Reflecting on progress and hope for the future in cancer treatment

PhRMA  |  Blog Post

Check out an interview with Marisa Dolled-Filhart, Ph.D., director of pathology and companion diagnostics at Merck, on her work as part of the oncology team.

Yep, Obamacare Costs a Fortune

Access Better Coverage  |  From Our Network

More important, and potentially worrisome for the law's defenders: Average deductibles for silver plans (the most popular type of exchange coverage) are about three times as high as on employer plans.

Study highlights negative impact of Canada's promise doctrine on R and D investment

PhRMA  |  Blog Post

For more information on Canada’s promise doctrine and its overall approach to IP, go to

You have reviewed the first 125 results out of 1971. Each page contains 25 results. You're on page 5.

prev 1 2 3 4 5 6 next